$Humanigen, Inc.(HGEN)$ $HGEN
UK’s MHRA accepts Humanigen’s submission of Lenzilumab for Marketing Authorization in COVID-19 for expedited rolling review
Despite surging cases , UK still plans a full reopening on July 17th. We can only hope that the MHRA have earmarked accelerated authorization for Lenzilumab to treat patients that become hospitalized as a result of this disastrous political decision.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
